<?xml version="1.0" encoding="UTF-8"?>
<ref id="B97-pharmaceuticals-13-00096">
 <label>97.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Cascella</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Rajnik</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Cuomo</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Dulebohn</surname>
    <given-names>S.C.</given-names>
   </name>
   <name>
    <surname>Di Napoli</surname>
    <given-names>R.</given-names>
   </name>
   <name>
    <surname>Xu</surname>
    <given-names>Z.</given-names>
   </name>
   <name>
    <surname>Shi</surname>
    <given-names>L.</given-names>
   </name>
   <name>
    <surname>Wang</surname>
    <given-names>Y.</given-names>
   </name>
   <name>
    <surname>Zhang</surname>
    <given-names>J.</given-names>
   </name>
   <name>
    <surname>Huang</surname>
    <given-names>L.</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Baricitinib as potential treatment for 2019-nCoV acute respiratory disease</article-title>
  <source>Lancet</source>
  <year>2020</year>
  <volume>395</volume>
  <fpage>565</fpage>
  <lpage>574</lpage>
  <pub-id pub-id-type="pmid">32007145</pub-id>
 </element-citation>
</ref>
